Related Experiment Video

Updated: May 9, 2026

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
07:04

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Published on: February 11, 2017

CCN2: a novel, specific and valid target for anti-fibrotic drug intervention

Andrew Leask1

  • 1The University of Western Ontario, Schulich School of Medicine & Dentistry, Department of Physiology & Pharmacology, Schulich Dentistry, London, Ontario, N6A 5C1, Canada. andrew.leask@schulich.uwo.ca

Expert Opinion on Therapeutic Targets
|July 16, 2013
PubMed
Abstract

Insights

Targeting matricellular proteins like CCN2 (connective tissue growth factor) offers a promising new strategy for anti-fibrotic therapies. These proteins are implicated in fibrosis and may overcome challenges faced by previous growth factor-focused approaches.

Area of Science:

  • Fibrosis research
  • Biochemistry
  • Drug discovery

Background:

  • Previous anti-fibrotic therapies targeted growth factors and cytokines.
  • These targets have essential roles in normal physiology, complicating drug development.
  • Developing effective anti-fibrotic treatments remains a significant challenge.

Purpose of the Study:

  • To explore novel therapeutic targets for fibrosis.
  • To investigate the role of matricellular proteins in fibrotic diseases.
  • To evaluate CCN2 as a potential anti-fibrotic drug target.

Main Methods:

  • Literature review of PubMed for studies on matricellular proteins and fibrosis.
  • Analysis of expression patterns of matricellular proteins, specifically CCN2.
  • Review of recent publications on CCN2's role in mediating fibrosis.

Main Results:

  • Matricellular proteins modulate cellular responses to growth factors and cytokines.
  • CCN2 (connective tissue growth factor) expression is frequently altered in fibrotic conditions.
  • Emerging data indicates CCN2 directly contributes to the development of fibrosis.

Conclusions:

  • Matricellular proteins, including CCN2, are potential ideal targets for novel anti-fibrotic therapies.
  • CCN2, a member of the CCN family, shows promise as a therapeutic target.
  • Targeting CCN2 may offer a more effective approach to treating fibrosis.

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...